-

Diality to Unveil Moda-flx Hemodialysis System, Poster Data at ASN Kidney Week 2023

Platform designed to deliver flexibility, ease of use and mobility in dialysis care

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc. today announced that it will introduce its Moda-flx Hemodialysis System™ at ASN Kidney Week 2023, Nov. 1-5 at the Pennsylvania Convention Center in Philadelphia. The technology will also be the subject of a poster session titled “Blood Flowrate Accuracy with Diality Hemodialysis System” [SA-P0618] to be presented from 10 a.m. to noon on Saturday, Nov. 4 in the exhibit hall.

Moda-flx is a patient-inspired hemodialysis system designed to empower healthcare professionals to choose what is best for patients, as well as their clinical practice. The Diality system, which is currently not approved for sale in any region, is designed to allow healthcare professionals to choose:

  • The right hemodialysis prescription in any care setting
  • The water/dialysate-generation option based on what works best for them
  • An interface that is easy to learn and use for specialists and non-nephrology clinicians

“Moda-flx is designed to deliver on Diality’s mission to improve lives impacted by kidney disease by reducing the burden of care for all kidney care stakeholders,” said Osman Khawar, M.D., chief executive officer for Diality. “We believe it will represent a new paradigm in the treatment of kidney disease, and we’re excited to introduce it to the kidney care community at Kidney Week.”

To view and learn more about the system, please visit Diality at ASN Kidney Week booth #2011.

About Diality

Headquartered in Irvine, Calif., Diality is a medical technology company developing a user-friendly, mobile, and connected hemodialysis system with a category-leading prescription range. The Diality system is designed to offer kidney care providers maximum flexibility as the market continues to evolve toward delivery of dialysis in a broader range of healthcare settings. Diality’s hemodialysis system is currently not approved for sale in any region. To learn more, please visit www.diality.com or find us on LinkedIn.

Contacts

MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Diality Inc.


Release Versions

Contacts

MEDIA CONTACT:
Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(860) 301-5058

Social Media Profiles
More News From Diality Inc.

Diality Appoints Peter Donato as Chief Financial Officer

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. Donato joins Diality with nearly 35 years of financial leadership experience, including ove...

Diality Announces Three Poster Presentations During The American Society of Nephrology (ASN) Kidney Week 2025

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc. today announced that three posters highlighting new data from the first clinical use of the Moda-flx™ Hemodialysis System will be presented during the American Society of Nephrology’s Kidney Week 2025 in Houston, Texas. “Real-World Urea Clearance and Adequacy with the Moda-flx Hemodialysis System” proves the system’s ability to leverage 600mL/min dialysate flow rate to achieve weekly clearance and ultrafiltration targets from the standard three hemo...

Diality Announces First Patient Treated in Moda-flx Home IDE PRESCRIBE Diality Clinical Trial

IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced the first patient treatment in its PRESCRIBE Diality Home Hemodialysis Clinical Trial in partnership with aQua Research Institute and aQua Dialysis in Houston, Texas. Diality is conducting the PRESCRIBE Diality trial under an Investigational Device Exemption (IDE) to evaluate a home use indication for the Moda-flx Hemodialysis System. The Moda-flx Hemodia...
Back to Newsroom